ArticleJournal of neuro-oncology2025
The impact of sociodemographic background on clinical presentation of high-grade gliomas: a multi-institutional retrospective analysis.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHigh-grade gliomas (HGG; WHO III/IV) are among the most devastating intracranial malignancies, and outcomes may be associated with demographic, biological and environmental factors. Although research exists on the association of sociodemographic background with outcomes, the literature lacks data on the effect of sociodemographic background on clinical presentation. In this study, we aimed to examine race- and ethnicity-related differences in HGG presentation and diagnosis.
methodsWe conducted a chart review of patients treated for HGG between 2015 and 2021 at three high-volume academic medical centers. A total of 314 patients were analyzed. 173 White patients were included along with 144 non-White patients, comprising of Asian (16%), Black (26%), Hispanic (9%), and other/declined (50%) race. Statistical analysis was carried out using GraphPad Prism.
resultsOn multivariate analysis, White race was significantly associated with a later age at diagnosis independent of IDH1 status. White patients were more likely to present with a cognitive deficit (42.3% vs. 21.1%; p = 0.02*), while less likely to present with midline shift (32.5% vs. 49.3%; p = 0.004**) and mass effect on imaging (59.8% vs. 76.1%; p = 0.003***). Additionally, Black patients were more likely to present with syncope (15.8% vs. 2.3% [n = 107]; p = 0.04*) and Hispanic patients were more likely to present with seizure (35.7% vs. 15.9% [n = 110]; p = 0.03*).
conclusionWhite race appears to be independently associated with a later age at diagnosis of HGG. Furthermore, Black and Hispanic patients are more likely to present with severe, life-threatening symptoms. Large-scale studies are needed to elucidate race-based differences in HGG presentation to effectively predict outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.